CONMED Corporation (CNMD)
- Previous Close
65.78 - Open
66.10 - Bid 64.72 x 900
- Ask 67.52 x 900
- Day's Range
65.48 - 67.25 - 52 Week Range
61.05 - 138.47 - Volume
494,088 - Avg. Volume
613,017 - Market Cap (intraday)
2.07B - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
25.75 - EPS (TTM)
2.61 - Earnings Date Jul 24, 2024 - Jul 29, 2024
- Forward Dividend & Yield 0.80 (1.22%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
94.86
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
www.conmed.comRecent News: CNMD
Performance Overview: CNMD
Trailing total returns as of 4/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNMD
Valuation Measures
Market Cap
2.03B
Enterprise Value
2.98B
Trailing P/E
25.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.65
Price/Book (mrq)
2.37
Enterprise Value/Revenue
2.36
Enterprise Value/EBITDA
13.88
Financial Highlights
Profitability and Income Statement
Profit Margin
6.53%
Return on Assets (ttm)
3.68%
Return on Equity (ttm)
10.25%
Revenue (ttm)
1.26B
Net Income Avi to Common (ttm)
82.35M
Diluted EPS (ttm)
2.61
Balance Sheet and Cash Flow
Total Cash (mrq)
33.85M
Total Debt/Equity (mrq)
115.93%
Levered Free Cash Flow (ttm)
168.06M
Research Analysis: CNMD
Company Insights: CNMD
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CNMD
CNMD: Lowering target price to $75.00
CONMED CORP has an Investment Rating of HOLD; a target price of $75.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetCNMD: Lowering target price to $81.00
CONMED CORP has an Investment Rating of HOLD; a target price of $81.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetCNMD: Raising target price to $84.00
CONMED CORP has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetCNMD: What does Argus have to say about CNMD?
CONMED CORP has an Investment Rating of HOLD; a target price of $81.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target